Compare BZFD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFD | TVRD |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 34.1M |
| IPO Year | N/A | N/A |
| Metric | BZFD | TVRD |
|---|---|---|
| Price | $0.79 | $3.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 184.7K | 39.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $292.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $3.50 |
| 52 Week High | $2.68 | $43.65 |
| Indicator | BZFD | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 44.71 | 47.62 |
| Support Level | $0.77 | $3.81 |
| Resistance Level | $0.84 | $4.39 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 57.39 | 54.93 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.